


Global Influenza Surveillance and Response System (GISRS)

Situation update on integrated sentinel surveillance of influenza and SARS-CoV-2 in SEAR Member States


(As of February 29, 2024 reported to RespiMart of GISRS)

Infectious Hazard Management (IHM)
WHO Health Emergency Programme
SeFlu@who.int


Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, SEAR




Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, SEAR




Number of ILI/SARI specimens processed for testing by week and year, SEAR




Number of specimens positive for influenza by subtypes and the percentage positive, SEAR




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, SEAR*




Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Bangladesh




Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Bangladesh




Number of ILI/SARI specimens processed for testing by week and year, Bangladesh




Number of specimens positive for influenza by subtypes and the percentage positive, Bangladesh




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Bangladesh




Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Bhutan




Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Bhutan




Number of ILI/SARI specimens processed for testing by week and year, Bhutan




Number of specimens positive for influenza by subtypes and the percentage positive, Bhutan




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Bhutan




Number and the proportion of influenza-like illness (ILI) cases* per 1 000 outpatients, [DPR Korea](#)




Number of severe acute respiratory infection (SARI) cases* per 100 inpatients, [DPR Korea](#)




Number of ILI/SARI specimens processed* for testing by week and year, DPR Korea




Number of specimens positive for influenza by subtypes* and the percentage positive, DPR Korea




Number of ILI/SARI specimens processed for testing by week and year, India




Number of specimens positive for influenza by subtypes and the percentage positive, India




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, India




Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Indonesia




Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Indonesia




Number of ILI/SARI specimens processed for testing by week and year, Indonesia




Number of specimens positive for influenza by subtypes and the percentage positive, Indonesia




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Indonesia




Number of ILI/SARI specimens processed for testing by week and year, Maldives




Number of specimens positive for influenza by subtypes and the percentage positive, Maldives




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Maldives




Number of ILI/SARI specimens processed for testing by week and year, Myanmar




Number of specimens positive for influenza by subtypes and the percentage positive, Myanmar




Number of influenza-like illness (ILI) cases, Nepal




Number of severe acute respiratory infection (SARI) cases , Nepal




Number of ILI/SARI specimens processed for testing by week and year, Nepal




Number of specimens positive for influenza by subtypes and the percentage positive, Nepal




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Nepal




Number and the proportion of influenza-like illness (ILI) cases* per 1 000 outpatients, [Sri Lanka](#)




Number and the proportion of severe acute respiratory infection (SARI) cases* per 100 inpatients, Sri Lanka




Number of ILI/SARI specimens processed for testing by week and year, Sri Lanka




Number of specimens positive for influenza by subtypes and the percentage positive, Sri Lanka




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Sri Lanka




Number of ILI/SARI specimens processed for testing by week and year, Thailand




Number of specimens positive for influenza by subtypes and the percentage positive, Thailand




Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Thailand




Number of influenza-like illness (ILI) cases, [Timor-Leste](#)




Number of severe acute respiratory infection (SARI) cases, Timor-Leste




Number of ILI/SARI specimens processed for testing by week and year, Timor-Leste



Number of specimens positive for influenza by subtypes and the percentage positive, Timor-Leste



Number and the percentage of ILI/SARI specimens positive for SARS COV-2, Timor-Leste



If you have any comment or suggestion
Please write to SeFlu@who.int